The maker of one of the costliest drugs in the world announced on Monday that it had struck deals with seven generic drug makers in India to sell lower-cost versions of the medicine — a $1,000-a-pill hepatitis C treatment — in poorer countries.
Gilead Sciences, which is based in California, also said it would begin selling its own version of the drug in India and other developing countries at a fraction of the price it charges in the United States.
The company intends to provide greater access to the medicine, Sovaldi, for most of the nearly 180 million infected worldwide with hepatitis C who do not live in rich countries. Some 350,000 people die every year of hepatitis C infections, most of them in middle- and low-income nations.
View original post 11 more words
James' World 2 
Leave a comment